A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

Hypertension: Does Novartis’s Tekturna Still Have What it Takes to Meet Expectations?

Based on our Pharmacor advisory service entitled Hypertension, Decision Resources is offering an exclusive analyst call entitled Hypertension: Does Novartis’s Tekturna Still Have What it Takes to Meet Expectations? Because this presentation will feature updates to the Hypertension topic, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

As the first in a new class of drugs in hypertension in more than 13 years, Novartis’s renin inhibitor Tekturna entered the market amid high expectations. However, since its launch in 2007, uptake of Tekturna has been disappointing. With few emerging therapies in development for the treatment of high blood pressure, emerging therapies face high barriers to entry in a market that is dominated by generic drugs that have well-established efficacy and safety. Undeterred, Novartis has expanded its Tekturna franchise with the launch of the fixed dose combinations, aliskiren/ hydrochlorothiazide (Tekturna HCT) and aliskiren/valsartan (Valturna). Additionally, the newest fixed-dose combinations, aliskiren/amlodipine and the triple therapy, aliskiren/amlodipine/hydrochlorothiazide, are currently in the preregistration stage.

This 15-minute analyst call, presented by Decision Resources Analyst Taskin Ahmed, will answer the following questions:

How is Tekturna being positioned by Novartis and how is it used in current medical practice?
Why has the uptake of Tekturna not met expectations and what are key opinion leaders saying about the prospects of the drug?
What challenges lie ahead for the Tekturna franchise if it is to replace Novartis’s multibillion dollar drug, Diovan?

Mr. Ahmed will conduct a live Q & A session after the presentation.

Registration

Hypertension: Does Novartis’s Tekturna Still Have What it Takes to Meet Expectations?

June 10, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Thursday, June 10, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Taskin Ahmed, MBA, is an analyst on the cardiovascular and metabolic disorders team at Decision Resources. Prior to joining the company, Mr. Ahmed held senior research analyst and editorial positions in consultancy and publishing companies, including PharmaVentures, Thomson Reuters and Intelligentsia. He has published articles and journals focusing on cardiovascular drug development and, more recently, in deals and alliances in the pharmaceutical and biotechnology industries. Mr. Ahmed earned an MBA from University of Surrey School of Management and a BSc in Pharmacology from King’s College London.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.